Broadleaf Partners LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 6,397 shares of the company’s stock, valued at approximately $894,000.
Several other large investors also recently made changes to their positions in JNJ. Eagle Ridge Investment Management boosted its stake in Johnson & Johnson by 3.5% in the 3rd quarter. Eagle Ridge Investment Management now owns 27,522 shares of the company’s stock worth $3,578,000 after purchasing an additional 928 shares during the period. Oliver Luxxe Assets LLC boosted its position in shares of Johnson & Johnson by 12.7% during the 2nd quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock valued at $2,320,000 after acquiring an additional 1,972 shares during the last quarter. Progressive Investment Management Corp boosted its position in shares of Johnson & Johnson by 6.8% during the 3rd quarter. Progressive Investment Management Corp now owns 40,317 shares of the company’s stock valued at $5,242,000 after acquiring an additional 2,584 shares during the last quarter. Middleton & Co Inc MA boosted its position in shares of Johnson & Johnson by 40.5% during the 3rd quarter. Middleton & Co Inc MA now owns 39,272 shares of the company’s stock valued at $5,106,000 after acquiring an additional 11,315 shares during the last quarter. Finally, Sitrin Capital Management LLC boosted its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Sitrin Capital Management LLC now owns 48,986 shares of the company’s stock valued at $6,480,000 after acquiring an additional 792 shares during the last quarter. Institutional investors own 67.21% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $125.10 on Monday. Johnson & Johnson has a twelve month low of $120.95 and a twelve month high of $148.32. The firm has a market capitalization of $335,631.06, a price-to-earnings ratio of 320.77, a P/E/G ratio of 1.99 and a beta of 0.77. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were paid a $0.84 dividend. The ex-dividend date was Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s payout ratio is 861.54%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.19% of the company’s stock.
A number of research analysts have recently commented on the company. JPMorgan Chase & Co. downgraded Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 target price for the company in a research report on Wednesday, December 20th. BMO Capital Markets increased their target price on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Jefferies Group set a $165.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, BTIG Research reiterated a “sell” rating and set a $110.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Four analysts have rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $146.06.
ILLEGAL ACTIVITY WARNING: This piece was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3301238/broadleaf-partners-llc-takes-894000-position-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.